FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to azetidine-substituted isoxazoline derivatives of formula (1), where A represents phenyl, naphtyl or heteroaryl, where said heteroaryl represents 5-6-membered aromatic monocyclic ring and contains 1 N heteroatom; each of R1a, R1b and R1c independently represents hydrogen, halogen, cyano, nitro or C1-C6halogenalkyl; R2 represents halogen, cyano or nitro; R3 represents hydrogen, halogen, hydroxyl, cyano, N3 or -NHR4; R4 represents hydrogen, -C(O)R5, -C(S)R5, -C(O)NRaR5, -S(O)pRc, -S(O)2NRaR5 or -C(NR7)R5; R5 represents hydrogen, C1-C6alkyl, C2-C6alkenyl, C0-C6alkylC3-C6cycloalkyl, C0-C6alkylphenyl, C0-C6alkylheteroaryl, representing 5-6-membered aromatic monocyclic ring, containing from 1 to 3 heteroatoms, each of which is independently selected from N, O and S, or C0-C6alkylheterocycle, where said heterocycle represents 4-membered monocyclic ring, containing 1 heteroatom, selected from N, O and S; R6 represents C1-C6halogenalkyl; R7 represents cyano; Ra represents hydrogen, C1-C6alkyl or C0-C3alkylC3-C6cycloalkyl; Rb represents hydrogen, C1-C6alkyl or C3-C6cycloalkyl; Rc represents C1-C6alkyl, C1-C6halogenalkyl, C1-C6halogenalkylC3-C6cycloalkyl, C0-C3alkylC3-C6cycloalkyl or C0-C3alkylphenyl, each of which is possibly substituted with at least one substituent, selected from cyano or halogen, each of groups C1-C6alkyl or C0-C3alkylC3-C6cycloalkyl ad R5 can be possibly and independently substituted with at least one substituent, selected from cyano, halogen, hydroxyl, C1-C6alkoxy, C1-C6halogenalkoxy, C1-C6halogenalkyl, -S(O)pRc, -SH, -S(O)pNRaRb, -NRaC(O)Rb, -SC(O)Rc and -C(O)NRaRb; and where grouping C0-C6alkylheteroaryl or C1-C6alkylheterocycle as R5 can be possibly additionally substituted with at least one substituent, selected from halogen, oxo, hydroxyl, C1-C6alkyl and -SH; n represents integer number 0 or 1, and p represents integer number 0, 1 or 2 and its stereoisomers. Invention also relates to pharmaceutical or veterinary composition, possessing parasiticidal activity, containing therapeutic amount of formula (I) derivative and pharmaceutically or veterinarily acceptable excipient, diluents or carrier.
EFFECT: azetidine-substituted isoxazoline derivatives of formula (1), intended for manufacturing means for treatment or control of parasitic infection or invasion in animal.
20 cl, 5 tbl, 225 ex
Title | Year | Author | Number |
---|---|---|---|
SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | 2012 |
|
RU2566083C2 |
AMIDES OF CONDENSED PIPERIDINE AS MODULATORS OF ION CHANNELS | 2014 |
|
RU2741810C2 |
MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
PESTICIDE COMPOSITIONS AND RELATED METHODS | 2012 |
|
RU2614976C2 |
QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING SAME | 2011 |
|
RU2582610C2 |
PESTICIDAL ARYLPYRROLIDINES | 2011 |
|
RU2578720C2 |
NOVEL BENZODIOXOLS | 2003 |
|
RU2304580C2 |
COMPOUNDS USEFUL AS PESTICIDES, AND INTERMEDIATE COMPOUNDS, COMPOSITIONS AND METHODS RELATED THERETO | 2016 |
|
RU2821715C2 |
COMPOUNDS FOR CANCER TREATMENT | 2009 |
|
RU2514427C2 |
MODULATORS OF NUCLEAR RECEPTORS | 2016 |
|
RU2715897C2 |
Authors
Dates
2015-05-20—Published
2011-07-27—Filed